Annexon Inc (ANNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Annexon Inc (ANNX) has a cash flow conversion efficiency ratio of -0.229x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.80 Million) by net assets ($204.53 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Annexon Inc (ANNX) total market value for the company's overall valuation and market capitalisation.
Annexon Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Annexon Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Annexon Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Annexon Inc ranked by their cash flow conversion efficiency. See Annexon Inc cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kvutzat Acro Ltd.
TA:ACRO
|
-0.030x |
|
Comintel Corporation Berhad
KLSE:7195
|
0.029x |
|
Everlight Chemical Industrial Corp
TW:1711
|
0.045x |
|
Shenyang Jinbei Automotive Co Ltd
SHG:600609
|
0.204x |
|
United States Antimony Corporation
NYSE:UAMY
|
-0.091x |
|
Miracll Chemicals Co Ltd
SHE:300848
|
0.054x |
|
Fitipower Integrated Technology Inc
TW:4961
|
0.004x |
|
Beijing SDL Technology Co Ltd
SHE:002658
|
0.054x |
Annual Cash Flow Conversion Efficiency for Annexon Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Annexon Inc from 2017 to 2025. View Annexon Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $211.65 Million | $-186.36 Million | -0.880x | -118.70% |
| 2024-12-31 | $293.11 Million | $-118.01 Million | -0.403x | +16.73% |
| 2023-12-31 | $250.56 Million | $-121.14 Million | -0.483x | +3.89% |
| 2022-12-31 | $231.19 Million | $-116.31 Million | -0.503x | -9.95% |
| 2021-12-31 | $231.91 Million | $-106.11 Million | -0.458x | -196.73% |
| 2020-12-31 | $344.28 Million | $-53.09 Million | -0.154x | +76.33% |
| 2019-12-31 | $43.53 Million | $-28.36 Million | -0.651x | -43.56% |
| 2018-12-31 | $37.88 Million | $-17.19 Million | -0.454x | -208.88% |
| 2017-12-31 | $-46.21 Million | $-19.26 Million | 0.417x | -- |
About Annexon Inc
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase… Read more